Mechanisms of metformin's anti-tumor activity against gemcitabine-resistant pancreatic adenocarcinoma

Keiichi Suzuki, Osamu Takeuchi, Yukio Suzuki, Yuukou Kitagawa

Research output: Contribution to journalArticle

Abstract

Metformin (MET) is the first-line treatment for type 2 diabetes mellitus. Several epidemiological studies have suggested the potential anti-cancer effects of MET, including its activity against pancreatic ductal adenocarcinoma (PDAC). Gemcitabine (GEM) has become the standard chemotherapy for PDAC; however, acquired resistance to GEM is a major challenge. In this study, we evaluated the anti-tumor effects of MET against GEM-resistant PDAC in a mouse xenograft model. GEM-resistant BxG30 PDAC cells were implanted into BALB/cnudemice.Themiceweredividedinto4groups(control, GEM, MET, and combined treatment with GEM + MET) and treated with the drugs for 4 weeks. Compared with the control mice, the final tumor volumes were significantly decreased in the mice treated with GEM + MET. Treatment to control volume ratios (T/C%) were calculated as 80.2% (GEM), 54.0% (MET) and 47.2% (GEM + MET). The anti-tumor activity of GEM alone against BxG30 tumor xenografts was limited. MET treatment alone exerted satisfactory anti-tumor effects; however, the optimal T/C% was achieved by treatment with GEM + MET, indicating that this combined treatment regimen potently inhibited the growth of GEM-resistant PDAC. The expression of hypoxia-inducible factor 1α (HIF-1α) and the phosphorylation of ribosomal protein S6 (S6), an important downstream effector of the mammalian target of rapamycin (mTOR) signaling pathway, were also assessed by western blot analysis. The phosphorylation of S6 was inhibited by incubation with MET, but not with GEM, and the expression of HIF-1α under hypoxic conditions was significantly inhibited by MET treatment, but not by GEM treatment. The production of vascular endothelial growth factor was also suppressed by MET treatment, but not by GEM treatment, as determined by ELISA. Taken together, the data of this study demonstrate that the anti-tumor activity of MET is mediated via the suppression of mTOR-HIF-1 signaling, reflecting a different underlying mechanism of action than that of GEM. These results may prove to be clinically significant and reveal the potential of MET as an effective therapeutic drug for PDAC.

Original languageEnglish
Pages (from-to)764-772
Number of pages9
JournalInternational journal of oncology
Volume54
Issue number2
DOIs
Publication statusPublished - 2019 Feb 1

Fingerprint

gemcitabine
Metformin
Adenocarcinoma
Neoplasms
Hypoxia-Inducible Factor 1
Therapeutics
S 6
Sirolimus
Heterografts

Keywords

  • Anticancer effect
  • Gemcitabine resistance
  • Hypoxia-inducible factor 1α
  • Mammalian target of rapamycin
  • Metformin
  • Pancreatic adenocarcinoma

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Mechanisms of metformin's anti-tumor activity against gemcitabine-resistant pancreatic adenocarcinoma. / Suzuki, Keiichi; Takeuchi, Osamu; Suzuki, Yukio; Kitagawa, Yuukou.

In: International journal of oncology, Vol. 54, No. 2, 01.02.2019, p. 764-772.

Research output: Contribution to journalArticle

@article{ab6dd06ea7b049a3b2cf44c5c329b806,
title = "Mechanisms of metformin's anti-tumor activity against gemcitabine-resistant pancreatic adenocarcinoma",
abstract = "Metformin (MET) is the first-line treatment for type 2 diabetes mellitus. Several epidemiological studies have suggested the potential anti-cancer effects of MET, including its activity against pancreatic ductal adenocarcinoma (PDAC). Gemcitabine (GEM) has become the standard chemotherapy for PDAC; however, acquired resistance to GEM is a major challenge. In this study, we evaluated the anti-tumor effects of MET against GEM-resistant PDAC in a mouse xenograft model. GEM-resistant BxG30 PDAC cells were implanted into BALB/cnudemice.Themiceweredividedinto4groups(control, GEM, MET, and combined treatment with GEM + MET) and treated with the drugs for 4 weeks. Compared with the control mice, the final tumor volumes were significantly decreased in the mice treated with GEM + MET. Treatment to control volume ratios (T/C{\%}) were calculated as 80.2{\%} (GEM), 54.0{\%} (MET) and 47.2{\%} (GEM + MET). The anti-tumor activity of GEM alone against BxG30 tumor xenografts was limited. MET treatment alone exerted satisfactory anti-tumor effects; however, the optimal T/C{\%} was achieved by treatment with GEM + MET, indicating that this combined treatment regimen potently inhibited the growth of GEM-resistant PDAC. The expression of hypoxia-inducible factor 1α (HIF-1α) and the phosphorylation of ribosomal protein S6 (S6), an important downstream effector of the mammalian target of rapamycin (mTOR) signaling pathway, were also assessed by western blot analysis. The phosphorylation of S6 was inhibited by incubation with MET, but not with GEM, and the expression of HIF-1α under hypoxic conditions was significantly inhibited by MET treatment, but not by GEM treatment. The production of vascular endothelial growth factor was also suppressed by MET treatment, but not by GEM treatment, as determined by ELISA. Taken together, the data of this study demonstrate that the anti-tumor activity of MET is mediated via the suppression of mTOR-HIF-1 signaling, reflecting a different underlying mechanism of action than that of GEM. These results may prove to be clinically significant and reveal the potential of MET as an effective therapeutic drug for PDAC.",
keywords = "Anticancer effect, Gemcitabine resistance, Hypoxia-inducible factor 1α, Mammalian target of rapamycin, Metformin, Pancreatic adenocarcinoma",
author = "Keiichi Suzuki and Osamu Takeuchi and Yukio Suzuki and Yuukou Kitagawa",
year = "2019",
month = "2",
day = "1",
doi = "10.3892/ijo.2018.4662",
language = "English",
volume = "54",
pages = "764--772",
journal = "International Journal of Oncology",
issn = "1019-6439",
publisher = "Spandidos Publications",
number = "2",

}

TY - JOUR

T1 - Mechanisms of metformin's anti-tumor activity against gemcitabine-resistant pancreatic adenocarcinoma

AU - Suzuki, Keiichi

AU - Takeuchi, Osamu

AU - Suzuki, Yukio

AU - Kitagawa, Yuukou

PY - 2019/2/1

Y1 - 2019/2/1

N2 - Metformin (MET) is the first-line treatment for type 2 diabetes mellitus. Several epidemiological studies have suggested the potential anti-cancer effects of MET, including its activity against pancreatic ductal adenocarcinoma (PDAC). Gemcitabine (GEM) has become the standard chemotherapy for PDAC; however, acquired resistance to GEM is a major challenge. In this study, we evaluated the anti-tumor effects of MET against GEM-resistant PDAC in a mouse xenograft model. GEM-resistant BxG30 PDAC cells were implanted into BALB/cnudemice.Themiceweredividedinto4groups(control, GEM, MET, and combined treatment with GEM + MET) and treated with the drugs for 4 weeks. Compared with the control mice, the final tumor volumes were significantly decreased in the mice treated with GEM + MET. Treatment to control volume ratios (T/C%) were calculated as 80.2% (GEM), 54.0% (MET) and 47.2% (GEM + MET). The anti-tumor activity of GEM alone against BxG30 tumor xenografts was limited. MET treatment alone exerted satisfactory anti-tumor effects; however, the optimal T/C% was achieved by treatment with GEM + MET, indicating that this combined treatment regimen potently inhibited the growth of GEM-resistant PDAC. The expression of hypoxia-inducible factor 1α (HIF-1α) and the phosphorylation of ribosomal protein S6 (S6), an important downstream effector of the mammalian target of rapamycin (mTOR) signaling pathway, were also assessed by western blot analysis. The phosphorylation of S6 was inhibited by incubation with MET, but not with GEM, and the expression of HIF-1α under hypoxic conditions was significantly inhibited by MET treatment, but not by GEM treatment. The production of vascular endothelial growth factor was also suppressed by MET treatment, but not by GEM treatment, as determined by ELISA. Taken together, the data of this study demonstrate that the anti-tumor activity of MET is mediated via the suppression of mTOR-HIF-1 signaling, reflecting a different underlying mechanism of action than that of GEM. These results may prove to be clinically significant and reveal the potential of MET as an effective therapeutic drug for PDAC.

AB - Metformin (MET) is the first-line treatment for type 2 diabetes mellitus. Several epidemiological studies have suggested the potential anti-cancer effects of MET, including its activity against pancreatic ductal adenocarcinoma (PDAC). Gemcitabine (GEM) has become the standard chemotherapy for PDAC; however, acquired resistance to GEM is a major challenge. In this study, we evaluated the anti-tumor effects of MET against GEM-resistant PDAC in a mouse xenograft model. GEM-resistant BxG30 PDAC cells were implanted into BALB/cnudemice.Themiceweredividedinto4groups(control, GEM, MET, and combined treatment with GEM + MET) and treated with the drugs for 4 weeks. Compared with the control mice, the final tumor volumes were significantly decreased in the mice treated with GEM + MET. Treatment to control volume ratios (T/C%) were calculated as 80.2% (GEM), 54.0% (MET) and 47.2% (GEM + MET). The anti-tumor activity of GEM alone against BxG30 tumor xenografts was limited. MET treatment alone exerted satisfactory anti-tumor effects; however, the optimal T/C% was achieved by treatment with GEM + MET, indicating that this combined treatment regimen potently inhibited the growth of GEM-resistant PDAC. The expression of hypoxia-inducible factor 1α (HIF-1α) and the phosphorylation of ribosomal protein S6 (S6), an important downstream effector of the mammalian target of rapamycin (mTOR) signaling pathway, were also assessed by western blot analysis. The phosphorylation of S6 was inhibited by incubation with MET, but not with GEM, and the expression of HIF-1α under hypoxic conditions was significantly inhibited by MET treatment, but not by GEM treatment. The production of vascular endothelial growth factor was also suppressed by MET treatment, but not by GEM treatment, as determined by ELISA. Taken together, the data of this study demonstrate that the anti-tumor activity of MET is mediated via the suppression of mTOR-HIF-1 signaling, reflecting a different underlying mechanism of action than that of GEM. These results may prove to be clinically significant and reveal the potential of MET as an effective therapeutic drug for PDAC.

KW - Anticancer effect

KW - Gemcitabine resistance

KW - Hypoxia-inducible factor 1α

KW - Mammalian target of rapamycin

KW - Metformin

KW - Pancreatic adenocarcinoma

UR - http://www.scopus.com/inward/record.url?scp=85058885517&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85058885517&partnerID=8YFLogxK

U2 - 10.3892/ijo.2018.4662

DO - 10.3892/ijo.2018.4662

M3 - Article

VL - 54

SP - 764

EP - 772

JO - International Journal of Oncology

JF - International Journal of Oncology

SN - 1019-6439

IS - 2

ER -